Immunotherapy Drugs Market – By Drug Type (Monoclonal Antibodies, Vaccines, Check Point Inhibitor, Interleukins), Application (Cancer, Autoimmune, Infectious), Route of Administration (Intravenous, Subcutaneous), Distribution Channel – Global Forecast (2024 – 2032)

Immunotherapy Drugs Market Size

Immunotherapy Drugs Market size was valued at USD 182.5 billion in 2023 and is expected to exhibit growth at a CAGR of 10.4% from 2024 and 2032. Immunotherapy drugs are a class of pharmaceutical compounds designed to modulate the body's immune system to treat diseases.
 

These drugs can be categorized into various types based on their mechanisms of action, including monoclonal antibodies, immune checkpoint inhibitors, cytokines, vaccines, adoptive cell therapies, and other immunomodulators. High market growth can be attributed to the ongoing advancements in biotechnology, increasing incidence and prevalence of cancer, rising healthcare expenditure, and expanding adoption of combination therapies, among other contributing factors.
 

Moreover, chronic diseases such as cancer, autoimmune disorders, and infectious diseases are becoming increasingly prevalent globally. Cancer, in particular, is a leading cause of morbidity and mortality worldwide. For instance, according to American Cancer Society, Inc. over 1.9 million new cancer cases were expected to be diagnosed in the U.S. in 2023. As the incidence of these diseases rises, there is a growing demand for effective treatment options that offer improved outcomes and fewer adverse effects, driving the growth of the immunotherapy drugs market.
 

Furthermore, immunotherapy drugs are not limited to oncology but are increasingly being explored and adopted across a wide range of disease areas, including autoimmune diseases, infectious diseases, allergies, and transplant rejection. This diversification of applications broadens the market opportunities for immunotherapy drugs and expands their reach to address unmet medical needs in different patient populations.
 

Immunotherapy Drugs Market Trends

The market is experiencing several notable trends that are shaping its growth and development. Factors such as continuous innovations in biologics and cell-based therapies, increased focus on personalized medicine, expansion of indications and combination therapies, and growing demand for integrated artificial intelligence in healthcare, among other factors are propelling the industry growth.
 

• Combination therapies involving multiple immunotherapy agents or immunotherapy with other modalities are being actively investigated in clinical trials and clinical practice. These combination approaches aim to enhance treatment efficacy, overcome resistance mechanisms, and improve patient outcomes by leveraging complementary mechanisms of action.
   
• Moreover, continuous advancements in biologics and cell-based therapies have propelled innovation in the market. Monoclonal antibodies, immune checkpoint inhibitors, CAR-T cell therapy, and other cell-based immunotherapies have emerged as transformative treatment modalities, offering new avenues for personalized medicine and targeted therapy, thereby aforementioned factors are expected to drive the market.
   

Immunotherapy Drugs Market Analysis

Based on drug type, the market is categorized into monoclonal antibodies, vaccines, check point inhibitor, interferons alpha & beta, interleukins, and other drug types. The monoclonal antibodies generated the highest revenue of USD 96.6 billion in 2023.
 

• Monoclonal antibodies are engineered to recognize and bind to specific antigens or molecular targets with high precision and specificity. This targeted approach allows for selective inhibition or activation of key pathways involved in disease pathogenesis, minimizing off-target effects and improving therapeutic outcomes.
   
• Additionally, these antibodies offer potent and durable therapeutic effects, often achieving higher efficacy rates and longer-lasting responses compared to conventional therapies. Their ability to selectively target disease-associated molecules or cells, coupled with their immunomodulatory properties, contributes to improved patient outcomes, including tumor regression, disease remission, and symptom relief.

Based on application, the immunotherapy drugs market is classified into cancer, autoimmune diseases, infectious diseases, and other applications. The cancer segment dominated the market in 2023 with a market share of 45.7%.
 

• Cancer remains one of the leading causes of morbidity and mortality worldwide, with a significant unmet medical need for effective treatments, particularly in advanced or refractory disease settings. Conventional therapies such as chemotherapy, radiation therapy, and surgery have limitations in terms of efficacy and tolerability, underscoring the need for novel therapeutic approaches like immunotherapy.
   
• Furthermore, rapid advancements in biotechnology have paved the way for the development of novel immunotherapy drugs with enhanced specificity, potency, and safety profiles. Breakthroughs such as monoclonal antibodies, immune checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines have revolutionized the treatment landscape, offering new avenues for targeted and personalized cancer therapy. This is anticipated to boost the segmental growth in the market.
   

Based on route of administration, the immunotherapy drugs market is classified into intravenous, subcutaneous, and oral. The intravenous segment dominated the market and is expected to grow at a pace of 10.3% CAGR between 2024 – 2032.
 

• Intravenous administration provides direct access to the bloodstream, allowing for rapid and efficient drug delivery to target tissues and systemic circulation. This ensures the timely and uniform distribution of immunotherapy drugs throughout the body, maximizing their bioavailability and therapeutic efficacy.
   
• Moreover, it enables precise dosing and titration of immunotherapy drugs, allowing healthcare providers to administer accurate doses tailored to individual patient characteristics, disease status, and treatment response. This precision in dosing facilitates optimal therapeutic outcomes while minimizing the risk of under- or overdosing, thus leading to the segmental growth.
   

Based on distribution channel, the immunotherapy drugs market is segmented into hospital pharmacy, brick and mortar, and e-commerce. The hospital pharmacy segment dominated the market in 2023 and is anticipated to reach USD 254.6 billion by the end of forecast period.
 

• Hospital pharmacies are committed to providing patient-centered care, ensuring that patients have access to the most effective and appropriate treatments, including immunotherapy drugs. Pharmacists collaborate with healthcare providers to optimize treatment regimens, educate patients about their medications, and support adherence to therapy, thereby maximizing the benefits of immunotherapy.
   
• Furthermore, these pharmacies play a critical role in the supply chain management of immunotherapy drugs, ensuring timely access to these medications for patients. Pharmacists collaborate with drug manufacturers, wholesalers, and distributors to procure and manage inventory, anticipate demand, and maintain adequate stock levels of immunotherapy drugs, minimizing disruptions in treatment availability and patient care.

North America immunotherapy drugs market accounted for USD 70.3 billion market revenue in 2023 and is anticipated to grow at CAGR of 10.2% between 2024 – 2032 period.
 

• North America faces a substantial burden of chronic diseases such as cancer, autoimmune disorders, and infectious diseases. This high disease burden creates a strong demand for innovative treatment options, including immunotherapy drugs, to address unmet medical needs and improve patient outcomes.
   
• Moreover, the region boasts a well-developed healthcare infrastructure comprising leading academic institutions, research centers, and healthcare facilities equipped with state-of-the-art technologies and expertise. This advanced infrastructure fosters a conducive environment for the research, development, and adoption of immunotherapy drugs, facilitating collaboration between industry stakeholders and academic researchers.
   

The U.S. held a dominant position in the immunotherapy drugs market, with a revenue of USD 65.1 billion in 2023.
 

• The U.S. is home to a thriving biopharmaceutical industry, with numerous companies leading the research, development, and commercialization of immunotherapy drugs. Major biopharmaceutical firms, including Merck & Co., Bristol Myers Squibb, Amgen, and Genentech, have headquarters or significant operations in the U.S., driving innovation and investment in immunotherapy research and development.
   
• Moreover, the U.S. is at the forefront of pioneering advances in precision medicine, leveraging genomic profiling, biomarker identification, and molecular diagnostics to tailor treatments to individual patients' genetic and molecular profiles.
   
• Biomarkers such as PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI) are utilized to predict treatment response and guide the selection of immunotherapy drugs, driving personalized medicine approaches, thereby driving the demand for immunotherapy drugs in the country.
   

Germany immunotherapy drugs market is projected to grow remarkably in the coming years.
 

• Germany boasts a robust healthcare system with high-quality medical infrastructure, well-trained healthcare professionals, and advanced research facilities. This supportive environment facilitates the development, approval, and adoption of innovative immunotherapy drugs.
   
• Additionally, the country has been at the forefront of personalized medicine initiatives, emphasizing the importance of tailored treatment approaches based on individual patient characteristics. Immunotherapy lends itself well to personalized medicine strategies, as it allows for the targeting of specific tumor antigens and immune pathways.
   

Japan holds a dominant position in the Asia Pacific immunotherapy drugs market.
 

• Japan is home to a well-developed pharmaceutical industry and has a strong research infrastructure, with leading pharmaceutical companies, academic institutions, and research organizations actively engaged in immunotherapy research and development.
   
• Collaboration between industry, academia, and government entities fosters innovation and accelerates the translation of scientific discoveries into clinical applications, driving the growth of the immunotherapy market in the country.
   

Immunotherapy Drugs Market Share

The market has surged due to rising cancer rates globally, advancements in biotechnology, and supportive regulatory policies. Immunotherapy offers targeted treatments, often with fewer side effects compared to conventional therapies, driving its adoption. Major pharmaceutical companies are heavily investing in R&D, expanding the range of immunotherapy drugs available, including immune checkpoint inhibitors, monoclonal antibodies, and CAR-T cell therapies. Combining therapies, personalized medicine, and exploring new indications further boost market growth. With ongoing innovation and collaboration, immunotherapy is poised to revolutionize cancer care and extend its impact to other medical fields.
 

Immunotherapy Drugs Market Companies

Prominent players operating in the immunotherapy drugs industry include:

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca
• Bayer AG
• Boehringer Ingelheim
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Genmab A/S
• GSK plc
• Immatics N.V.
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Novartis AG
• Pfizer, Inc.
• Sanofi
   

Immunotherapy Drugs Industry News:

• In May 2024, Amgen announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA (tarlatamab-dlle) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have progressed after platinum-based chemotherapy. IMDELLTRA has been granted fast approval due to the encouraging response rate and duration of response (DoR) found in clinical trials.
   
• In February 2022, Johnson & Johnson announced that CARVYKTI (ciltacabtagene autoleucel; cilta-cel) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with refractory or relapsed multiple myeloma (RRMM) adhering to four or more prior lines of therapy, which included an immunomodulatory agent, an anti-CD38 monoclonal antibody, and a proteasome inhibitor.
   

The immunotherapy drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Type

• Monoclonal antibodies
• Vaccines
• Check point inhibitor
• Interferons alpha & beta
• Interleukins
• Other drug types

Market, By Application

• Cancer
• Autoimmune diseases
• Infectious diseases
• Other applications

Market, By Route of Administration

• Intravenous
• Subcutaneous
• Oral

Market, By Distribution Channel

• Hospital pharmacy
• Brick and mortar
• E-commerce

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa